biotech / news / / Barchart
Eli Lilly (LLY) stock closed notably down on April 24 following reports that its newly launched oral obesity pill, Foundayo, is trailing Novo Nordisk’s (NVO) oral Wegovy in initial uptake.
Foundayo recorded only about 3,700 prescriptions in its second week versus 18,400 for oral Wegovy.
KEY POINTS
- Lilly’s total GLP-1 prescriptions declined by 0.3% week-over-week, per IQVIA data ending April 17.
- Lilly still commands an estimated 59% share of new GLP-1 prescriptions despite Foundayo’s slow start.
- Lilly’s debt-to-EBITDA ratio is projected to fall below 1x this year, improving financial flexibility.
- LLY’s partnership with Hims & Hers expands access to Zepbound and Foundayo via LillyDirect pharmacy.
COMPANIES
Summarized by Newsio from Barchart. How we summarize →